NDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
GANIRELIX ACETATE (ganirelix acetate) by Merck & Co. is clinical pharmacology the pulsatile release of gnrh stimulates the synthesis and secretion of luteinizing hormone (lh) and follicle-stimulating hormone (fsh). First approved in 1999.
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ganirelix Acetate is a GnRH receptor antagonist injectable used in assisted reproductive technology (ART) to prevent premature ovulation during fertility treatment. It competitively blocks GnRH receptors on pituitary gonadotrophs, inducing rapid and reversible suppression of LH and FSH secretion. The drug enables controlled ovarian stimulation by suppressing the natural LH surge that would otherwise trigger premature egg release.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling downsizing or transition planning for the brand team.
Mechanism of Action
CLINICAL PHARMACOLOGY The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient…
Worked on GANIRELIX ACETATE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.